Structure Therapeutics Inc.
GPCRNasdaqHealthcare · Pharmaceutical Preparations · E9 · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | −$176.6M | −$158.2M | −$102.8M | −$52.6M |
| Net income | −$141.2M | −$122.5M | −$89.6M | −$51.3M |
| Total assets | $1.58B | $903.3M | $482.0M | $97.8M |
| Total liabilities | $67.5M | $38.5M | $29.1M | $13.0M |
| Equity | $1.52B | $864.8M | $453.0M | −$115.1M |
| EPS (diluted) | $-0.80 | $-0.78 | $-0.81 | $-5.51 |
| Shares out. | 172.0M | 139.8M | 139.2M | 10.5M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −9.3%
- Return on assets
- −8.9%
- Return on capital (ROCE)
- −11.6%
- Liabilities / assets
- 4.3%
- Debt / equity
- 0.04×
- Book value / share
- $8.81
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 28.10safe
- Accruals / assets
- 5.1%moderate
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 1 warning● 2 good- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 14, 2023
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Biotechnology Value Fund L PPassive (13G)Feb 17, 2026
- Deep Track Capital, LpPassive (13G)Feb 13, 2026
- Wellington Management Group LlpPassive (13G)Feb 10, 2026
- Fmr LlcPassive (13G)Feb 5, 2026
- Janus Henderson Group PlcPassive (13G)Nov 14, 2025
- Avoro Capital Advisors LlcPassive (13G)Nov 14, 2025
- Capital Research Global InvestorsPassive (13G)May 13, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 5.7M | 7.3 | -5.4% |
| Apr 30, 2026 | 6.0M | 6.8 | -2.8% |
| Apr 15, 2026 | 6.1M | 6.1 | +6.8% |
| Mar 31, 2026 | 5.8M | 4.7 | +9.4% |
| Mar 13, 2026 | 5.3M | 7.1 | +0.6% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · Results of operations · Other material eventMay 7, 2026
- Director / officer change · Regulation FD disclosureApr 15, 2026
- Regulation FD disclosure · Other material eventMar 16, 2026
- Results of operationsFeb 26, 2026
- Entered a material agreementJan 5, 2026
- Other material eventDec 10, 2025
- Regulation FD disclosure · Other material eventDec 8, 2025
- Results of operationsNov 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.